Navigation Links
AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Date:9/5/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Sept. 5 /PRNewswire-FirstCall/ - AKELA Pharma Inc., (TSX: AKL), a drug development company focused on developing therapies for the inhalation, pain and CNS markets, today announced positive results from the double-blind extension part of its Fentanyl TAIFUN(R) Phase IIb trial. The results demonstrated statistically significant differences compared to placebo in the measured primary and secondary efficacy variables resulting in faster and superior pain relief. Fentanyl TAIFUN(R) is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform.

A total of 50 patients were randomized and started the extension part of the study. In the Intent-To-Treat (ITT) population, the median time to significant pain relief in the Fentanyl TAIFUN(R) group as measured by a decrease of at least 2 points on the numerical pain scale (NPS) was 5.2 minutes, which was statistically significantly faster when compared to placebo (P=0.007). The mean difference in sum of pain intensity difference (SPID) was also statistically significantly in favor of Fentanyl TAIFUN(R) for the whole 60 min pain episode (P=0.050). This was already seen in numerical pain scale scores up to 15 minutes (P=0.008) when compared to placebo.

"We are extremely satisfied to have demonstrated beyond doubt the faster and superior pain relief provided by Fentanyl TAIFUN(R) to patients. The additional knowledge and data accumulated during this clinical trial, as well as the positive feed-back by the authorities during the recent End-of-Phase II meetings makes us confident when preparing our Phase III study protocols." said Dr. Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc.

Phase IIb for Fentanyl TAIFUN(R) was a multi-center, multinational clinical trial in cancer patients with severe persistent pain on main
'/>"/>

SOURCE AKELA PHARMA INC.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Setting up a new pharmaceutical industry in India
7. Medicis Pharmaceutical company enters pediatric market
8. Supply of Radiopharmaceuticals Hampered by Attacks
9. Pharma majors gear to supply anti-anthrax drug
10. Pharmacies in for a dose of bitter medicine
11. Andhra Pradesh to set up Pharma City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
... survey, biting a bar of chocolate every day is co...h chocolates are high in fat and sugar, it has lon..., recent evidence suggests that, like other plant ...xidants, which can protect from chronic disease. ...
...tudy which suggests hormone suppression therapy co...ncer patient's chances of living free of the disea...y Hospital, examined the potential benefits of sup...e more commonly known male hormone testosterone, a...
... amount of fluids should be taken, in order to rep...er is far better than 'energy' drinks for keeping ...is maximum need for fluids,// henceforth, you'll b...ls topped up with regular drinks. There are a lot ...
...ch are protective substances, produced by the body...m kill the TB bacteria, researchers in the UK repo... journal Nature Medicine,// these heat-shock prote...body help cells survive stressful times and bolste...
Other Medicine News:Health News:Hormone Therapy applicable for Prostate Cancer 2
(Date:5/21/2008)... HILDEN, Germany, May 21 /...V Test as Front-line,Screen, Long-term data from ...Cancer show that women screened only with a human ...o develop moderate to severe cervical disease over...onal cytology (the Pap,"smear"). The research foll...
(Date:5/20/2008)...Statistically Significant Reduction of IBS Pain an...Effect Observed, SAN DIEGO, May 20 /...results of a recent Phase 2b study of its oral kap...onstrated statistically significant,results in the...adoline,produced significant improvement in diarrh...
(Date:5/20/2008)... 94 Percent of Men Maintained Normal Testosteron...Treatment 92 Percent of Men Expressed Sat...- Indevus,Pharmaceuticals, ... NEBIDO(R),(testosterone undecanoate), an investig...he treatment of hypogonadism, was presented in a l...
(Date:5/20/2008)...ata on Newly-Approved Cimzia(R) Presented at Diges...swire/ -- UCB announced today that data,presented ...sustainable,efficacy and safety of Cimzia(R) (cert...ts with moderate to severe Crohn,s disease. Data a...y of responders and the remission,rate remained st...
Breaking Medicine Technology:Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 2Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 3Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 4Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 2Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 3Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 4Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 2Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 3Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 2Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 3Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 5Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 6Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 7Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 8BLU MED Announces New Medical Preparedness Contracts 7283 1BLU MED Announces New Medical Preparedness Contracts 7283 2BioSpace Launches 2nd Edition of Southern Pharm 28TM 29 Hotbed Campaign 2027 1BioSpace Launches 2nd Edition of Southern Pharm 28TM 29 Hotbed Campaign 2027 2U S Patent 7 299 083 Awarded to Signalife 2023 1U S Patent 7 299 083 Awarded to Signalife 2023 2FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 1FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 2FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 3FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 4
...uture Pandemics , ,BETHESDA, Md., April 2, 2007--O...anish influenza pandemic is why it struck differen...cipalities such as,St. Louis spared the fate of th...emented similar public health measures? What made ...es funded by the,National Institutes of Health (NI...
...ent Therapy Significantly,Improved Absorption of F...y and DAYTON, Ohio, April 04, 2007 /PRNewswire/ --..., today unveiled,data from two phase III clinical ... formerly EUR-1008, for the treatment of,Exocrine ...ug,Administration (FDA) granted fast track status ...
Other Medicine Technology:Rapid Response was Crucial to Containing the 1918 Flu Pandemic 2Rapid Response was Crucial to Containing the 1918 Flu Pandemic 3Rapid Response was Crucial to Containing the 1918 Flu Pandemic 4Rapid Response was Crucial to Containing the 1918 Flu Pandemic 5Eurand Announces Positive Phase III Clinical Study Results 2Eurand Announces Positive Phase III Clinical Study Results 3Eurand Announces Positive Phase III Clinical Study Results 4Eurand Announces Positive Phase III Clinical Study Results 5
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety.
The 5500s electronic architecture incorporates advanced circuit designs optimized for efficiency and function. We call it HI VUE an engineering philosophy that directs the development of each subsys
The HI VISION 6500 high resolution digital ultrasound system offers advanced clinical imaging, enhanced operating efficiency, and remarkable clinical flexibility, all in robust and versatile configur
...features of the ELECTRA 1400C are designed to achi...away capabilities. This system includes automated ...nogen and factor assays in a single setup. It also...eparation of reference curves and patient sample d...
Medicine Products: